Publications by authors named "D L DENNIS"
Movement pattern biofeedback training after total knee arthroplasty: a randomized controlled trial.
Arthritis Care Res (Hoboken)
December 2024
Objective: Habitual movement compensations, such as decreased surgical peak knee extension moments (pKEM), persist years after total knee arthroplasty (TKA), are linked to poorer recovery, and may influence contralateral osteoarthritis (OA) progression. The purpose of this randomized clinical trial was to determine if a movement training program (MOVE) improves movement quality and recovery after TKA compared to a standardized rehabilitation program without movement training (CONTROL).
Methods: One hundred thirty-eight individuals were randomized to either MOVE or CONTROL groups after TKA.
Dr. Sylvester J. Carter: First Black American Hand Surgeon and Early Pioneer in Hand Surgery.
Plast Reconstr Surg Glob Open
November 2024
Article Synopsis
- To perform successful total hip arthroplasty (THA), surgeons must accurately restore the patient's anatomical structure and soft-tissue tension, particularly focusing on the restoration of femoral offset.
- This review aims to define how femoral offset is measured, its significance in hip joint biomechanics, and how incorrect offset can lead to complications such as pain, instability, and decreased motor performance.
- The review also examines intraoperative factors and the selection and positioning of prosthetic implants to enhance stability and functional outcomes post-surgery.
Article Synopsis
- Water-soluble prodrug technology has potential for improving the oral bioavailability of insoluble small molecule drugs, but it's not widely used due to rapid breakdown in the gastrointestinal tract that leads to ineffective drug absorption.
- Researchers developed a new water-soluble promoiety (Sol-moiety) technology aimed at slowing the hydrolysis of prodrugs, enhancing drug absorption instead of causing precipitation.
- The effectiveness of this technology was shown by significantly improving the pharmacokinetics of drugs like enzalutamide, vemurafenib, and paclitaxel, including a successful study on a paclitaxel prodrug in a mouse model for pancreatic tumors.